Overview

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

Status:
Completed

Trial end date:
2013-05-16

Target enrollment:

Participant gender:

Summary

To assess the efficacy of optimized Extended-release Guanfacine Hydrochloride compared with placebo in the treatment of adolescents aged 13-17 years with a diagnosis of ADHD as measured by the ADHD-RS-IV

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Guanfacine